Citi raised the firm’s price target on Applied Therapeutics to $7 from $5 and keeps a Buy rating on the shares. Following the positive interim update, the analyst added sorbitol dehydrogenase deficiency to the model with a 70% probability of success. The firm also raised pricing assumptions for govorestat to $370,000 per year to better reflect the rare disease pricing model established in comparably scaled markets.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See today’s best-performing stocks on TipRanks >>
Read More on APLT:
- Applied Therapeutics’ Govorestat Shows Promise in Phase 3 Trial
- Biotech Alert: Searches spiking for these stocks today
- Applied Therapeutics announces topline results of ARISE-HF Phase 3 of AT-001
- Applied Therapeutics Announces Topline Results from the ARISE-HF Phase 3 Study of AT-001 in Diabetic Cardiomyopathy
- Applied Therapeutics announces MAA validation, NDA submission for AT-007
